Live feed09:00:00·16dPRReleaseMAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer TherapyMAIA· MAIA Biotechnology Inc.Health CareOriginal source
